Singular Genomics Systems Inc
NASDAQ:OMIC
Net Margin
Singular Genomics Systems Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | US |
Market Cap | 27.4m USD |
Net Margin |
-3 257%
|
Country | US |
Market Cap | 229.7B USD |
Net Margin |
14%
|
Country | US |
Market Cap | 195.9B USD |
Net Margin |
18%
|
Country | US |
Market Cap | 45.4B USD |
Net Margin |
18%
|
Country | US |
Market Cap | 42.1B USD |
Net Margin |
9%
|
Country | CH |
Market Cap | 38.1B CHF |
Net Margin |
10%
|
Country | KR |
Market Cap | 56.1T KRW |
Net Margin |
23%
|
Country | US |
Market Cap | 32.3B USD |
Net Margin |
21%
|
Country | IE |
Market Cap | 26B USD |
Net Margin |
8%
|
Country | US |
Market Cap | 25.6B USD |
Net Margin |
19%
|
Country | US |
Market Cap | 21.1B USD |
Net Margin |
21%
|
Profitability Report
View the profitability report to see the full profitability analysis for Singular Genomics Systems Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Singular Genomics Systems Inc's most recent financial statements, the company has Net Margin of -3 257.3%.